title: Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD.
authors.affiliation: Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany magnussen@pulmoresearch.de.
authors.forename: Helgo
authors.initials: H
authors.lastname: Magnussen
authors.affiliation: Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany.
authors.forename: Kay
authors.initials: K
authors.lastname: Tetzlaff
authors.affiliation: Division of Pulmonology, Dept of Medicine, University of Cape Town, Cape Town, South Africa.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Bateman
authors.affiliation: Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
authors.forename: Henrik
authors.initials: H
authors.lastname: Watz
authors.affiliation: Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Kirsten
authors.affiliation: Dept of Respiratory Medicine, University Hospital Maastricht, Maastricht University, Maastricht, The Netherlands.
authors.forename: Emiel F M
authors.initials: EF
authors.lastname: Wouters
authors.affiliation: Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany.
authors.forename: Bernd
authors.initials: B
authors.lastname: Disse
authors.affiliation: Dept of Biometry and Data Management, Boehringer Ingelheim, Bracknell, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Finnigan
authors.affiliation: Servei de Pneumologia, Hospital Clínic IDIBAPS-CIBERES, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Rodriguez-Roisin
authors.affiliation: Institute of Ageing and Chronic Disease, Aintree University Hospital, Liverpool, UK.
authors.forename: Peter M A
authors.initials: PM
authors.lastname: Calverley
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068298:Fluticasone / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D000068299:Salmeterol Xinafoate / Q000627:therapeutic use; D012720:Severity of Illness Index; D000069447:Tiotropium Bromide / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D018727:Muscarinic Antagonists; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000069447:Tiotropium Bromide